Stifel Maintains Buy on DarioHealth, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst David Grossman has maintained a Buy rating on DarioHealth (NASDAQ:DRIO) and kept the price target at $4. This reaffirms Stifel's positive outlook on the company's stock.
April 01, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst David Grossman reaffirms a Buy rating on DarioHealth with a $4 price target, indicating a positive outlook on the stock.
The maintenance of a Buy rating and a $4 price target by a Stifel analyst suggests a strong belief in the company's potential for growth or recovery. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100